Efficacy of empagliflozin in patients with metabolic dysfunction-associated steatotic liver disease with or without diabetes: a systematic review and meta-analysis of randomized controlled trials.

Front Med (Lausanne) · 2025 · PMC12914734 · PMID 41717349

Europe PMC DOI

hedged sentences

0.0940

closest p · 1.9× alpha

0.0940

boldest claim

The sentences

did not reach statistical significancep = 0.094so close (0.05 < p ≤ 0.1)

28.6%), this difference did not reach statistical significance ( p = 0.094).

also in 111,027 other papers

failed to reach statistical significanceno p-value reported

Despite these improvements in liver enzymes, the analysis did not reveal significant differences between empagliflozin and placebo in terms of non-invasive liver fibrosis and steatosis markers, including CAP, LSM, APRI, NFS, and FIB-4, but it is important to consider that the MD was favoring empagliflozin and the sample size was small, which may have failed to reach statistical significance.

also in 6,035 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.